NEW YORK — September 9, 2026
Schrödinger, Inc. announced the formation of Tectora Therapeutics, a new biotechnology company focused on developing innovative oral therapies for immunology and inflammation. The company was co-founded by Schrödinger, New Enterprise Associates (NEA) and RA Capital Management and simultaneously closed a $55 million Series A financing led by NEA and RA Capital. The transaction represents another example of Schrödinger’s strategy of combining its computational drug discovery capabilities with external capital and biotechnology expertise to advance early-stage programs. Tectora will focus on translating clinically validated biology into differentiated oral medicines for immune-mediated diseases, with the objective of addressing areas of significant unmet patient need.
Tectora Acquires Two Schrödinger Drug Programs
As part of the formation, Schrödinger contributed two early-stage small-molecule programs, SDGR-4594 and SDGR-8139, to Tectora. In exchange, Schrödinger received an equity stake in Tectora and remains eligible for future development milestones and royalties associated with the programs. The new company will work closely with Schrödinger’s therapeutics R&D organization and use the company’s computational platform at scale to progress the assets toward clinical candidates. This structure allows Schrödinger to retain economic exposure to the programs while providing Tectora with dedicated financing and an independent operating framework. The collaboration is designed to combine computational molecular discovery, drug-design expertise and preclinical capabilities with the capital required to advance potentially high-value immunology and inflammation programs.
$55 Million Financing Supports Preclinical Development
The $55 million Series A provides Tectora with dedicated capital to advance its initial portfolio through preclinical development and toward the clinic. NEA and RA Capital are participating as founding investors alongside Schrödinger, bringing biotechnology investment and company-building expertise to the new venture. Tectora’s strategy is centered on developing convenient oral medicines for immune-mediated diseases, particularly by targeting biology that has already demonstrated clinical validation but may benefit from improved therapeutic approaches. Schrödinger said the collaboration reflects its broader model of creating and enabling drug-development programs through licensing transactions and venture-backed biotechnology companies. According to the company, partnerships involving Nimbus, Morphic, Structure and Ajax have collectively generated more than $750 million in proceeds for Schrödinger, highlighting the strategic importance of its platform-driven externalization model.
Advertisement
Schrödinger Expands Computational Drug Discovery Model
The launch of Tectora strengthens Schrödinger’s strategy of using computational drug discovery to create new biotechnology companies and advance medicines beyond early discovery. Schrödinger’s platform has been developed through more than 30 years of R&D investment and is used by biotechnology, pharmaceutical, industrial and academic organizations worldwide. For Tectora, access to the platform and Schrödinger’s internal drug discovery team is expected to support molecular optimization and the progression of SDGR-4594 and SDGR-8139 toward clinical candidates. The company intends to build a broader pipeline addressing immunology and inflammation, while its investors view the combination of validated targets, computational discovery and dedicated financing as a foundation for development against historically challenging disease areas. With $55 million in Series A funding and two proprietary small-molecule programs transferred from Schrödinger, Tectora represents a new extension of the company’s biotechnology venture-creation strategy and establishes a dedicated platform for advancing oral immune-mediated disease therapies.
Source:Schrödinger, press release
